← GE HealthCare overview

GE HealthCare vs Agilent: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

GE HealthCare Technologies Inc. (GEHC)

Q3 2026
▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

  • Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.

    The Q2 earnings beat is the main new event driving the stock this period.

  • $500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.

    A major new contract that directly boosts future revenue and investor confidence.

  • CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.

    New negative developments that create uncertainty and could pressure the stock.

  • Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.

    A new collaboration that showcases GEHC's technology and potential for future growth.

July 2026
▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

  • Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.

    The Q2 earnings beat is the main new event driving the stock this period.

  • $500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.

    A major new contract that directly boosts future revenue and investor confidence.

  • CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.

    New negative developments that create uncertainty and could pressure the stock.

  • Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.

    A new collaboration that showcases GEHC's technology and potential for future growth.

Latest
▲3▼1

GEHC beats Q2, wins $500M deal, but CFO exit and fraud probe weigh

  • Q2 beat and record backlog GEHC beat Q2 revenue and profit estimates, with organic orders up 11% and a record $23.9 billion backlog. This shows demand is strong and future sales are locked in, pushing the stock up as investors gain confidence in growth.

    The Q2 earnings beat is the main new event driving the stock this period.

  • $500M Catholic Health deal GEHC signed a 10-year, $500 million deal to supply over 1,300 machines and AI tools to Catholic Health. This adds a large, predictable revenue stream and shows its equipment is in demand, supporting the stock price.

    A major new contract that directly boosts future revenue and investor confidence.

  • CFO departure and fraud investigation CFO James Saccaro will step down on August 14, and a law firm is investigating possible securities fraud tied to the April Q1 earnings miss and guidance cut. These raise uncertainty about management and legal risks, which can weigh on the stock.

    New negative developments that create uncertainty and could pressure the stock.

  • Mayo Clinic theranostics study GEHC and Mayo Clinic launched a study using GEHC's StarGuide SPECT/CT to personalize prostate cancer treatment. This highlights its technology in a growing area, which can boost future sales and support the stock.

    A new collaboration that showcases GEHC's technology and potential for future growth.

Q2 2026
▲3▼1

GEHC's AI product wins offset by weak profit guidance

  • Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.

    This is the biggest new event of the period and directly explains the stock's drop.

  • FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.

    A new regulatory approval expands the product portfolio and is a fresh positive catalyst.

  • RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.

    A new analyst rating is a fresh event that directly lifted the stock on the day.

  • AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.

    Shows the company's long-term growth potential in AI, a key theme for future earnings.

June 2026
▲3▼1

GEHC's AI product wins offset by weak profit guidance

  • Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.

    This is the biggest new event of the period and directly explains the stock's drop.

  • FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.

    A new regulatory approval expands the product portfolio and is a fresh positive catalyst.

  • RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.

    A new analyst rating is a fresh event that directly lifted the stock on the day.

  • AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.

    Shows the company's long-term growth potential in AI, a key theme for future earnings.

▲3▼1

GEHC's AI product wins offset by weak profit guidance

  • Weak profit guidance drags stock GE HealthCare beat revenue expectations but missed full-year earnings guidance, sending shares down 11.1% to $60.91. Investors worry that costs or pricing pressure are eating into profits even as sales grow, which weighs on the stock.

    This is the biggest new event of the period and directly explains the stock's drop.

  • FDA clearance for AI radiation therapy tool GE HealthCare won FDA clearance for AI software that automates radiation therapy planning, making it faster and more personalized. This adds a new product to its oncology lineup and supports future revenue growth.

    A new regulatory approval expands the product portfolio and is a fresh positive catalyst.

  • RBC initiates with Outperform, stock jumps RBC started covering GE HealthCare with an Outperform rating, helping shares gain 5.08% even as broader markets fell. Analyst backing can boost investor confidence and attract new buyers.

    A new analyst rating is a fresh event that directly lifted the stock on the day.

  • AI imaging showcase and market growth GE HealthCare presented new AI imaging tools at medical conferences and the AI medical device market is projected to grow 27% yearly to $42 billion by 2030. Its $3 billion Caption Health deal positions it in this fast-growing area.

    Shows the company's long-term growth potential in AI, a key theme for future earnings.

Agilent Technologies Inc (A)

Q3 2026
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

August 2026
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Latest
▲3▼1

Agilent lifts guidance as China rebounds and diagnostics expand

  • AI cell analysis software and strong Q3 outlook Agilent launched AI-powered cell analysis software and guided Q3 revenue to $1.83–1.85 billion, above consensus. This shows its products are in demand and management is confident, which supports a higher stock price.

    New product and guidance signal future growth, a key driver for the stock.

  • FDA and EU approvals for cancer companion diagnostics Agilent won FDA and EU approvals for its PD-L1 tests in esophageal, gastric, and ovarian cancers. These tie its tests to blockbuster drugs, expanding its diagnostics business and adding steady revenue, which lifts the stock.

    Regulatory wins open new markets and deepen partnerships, directly boosting future sales.

  • Raised FY2026 guidance on China rebound and pharma growth Agilent raised full-year EPS guidance to $6.18–$6.21 after Q3 revenue rose 7.3% and China grew 9%. Strong pharma and advanced therapeutics demand, plus a $1 billion reshoring opportunity, point to faster growth ahead.

    Guidance raise and China recovery are the biggest new fundamental drivers for the stock.

  • Competition and sector sensitivity remain risks Danaher's Leica is expanding in pathology, and the life sciences tools sector is sensitive to growth outlook cuts. These pressures could cap Agilent's gains if investors worry about market share or a broader slowdown.

    Provides a fair counterweight to the positive news, showing what could hold the stock back.

Q2 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

June 2026
▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

▲4

Agilent beats earnings, raises guidance, completes Biocare acquisition

  • Earnings beat and raised guidance Agilent reported Q2 earnings of $1.49 per share, up 13.7% and beating estimates, with revenue up 10% to $1.84 billion. The company raised full-year guidance, signaling strong business momentum and boosting investor confidence.

    This is the core financial result that directly drives the stock and shows the company's health.

  • Biocare acquisition completed Agilent completed its acquisition of Biocare Medical, a cancer diagnostics firm. The deal is expected to boost growth, margins, and earnings per share within a year, expanding Agilent's pathology business and driving the stock up 4.5% on the news.

    This is a major strategic move that directly affects future growth and profitability.

  • China Innovation Center and AI push Agilent announced a new China Innovation Center focused on digital, AI, and automation R&D. This expands its capabilities in high-growth areas and positions it for long-term demand, though execution risks remain.

    It shows Agilent investing in future technologies and markets, which can drive growth.

  • Drug discovery market growth The drug discovery technologies market is projected to grow 11% annually to $51.5 billion by 2030, with AI-based tools leading. As a key player, Agilent stands to benefit from this expanding demand for its products and services.

    It highlights a favorable industry trend that supports Agilent's revenue growth.

© 2026 MarketIVWhy